AbbVie to Bolster its Immunology Pipeline Through the Acquisition of Nimble Therapeutics
Shots:
- AbbVie has signed a definitive agreement to acquire Nimble Therapeutics for $200M upfront, plus interim funding and a potential milestone payment
- The acquisition adds Nimble’s preclinical oral peptide IL23R inhibitor for psoriasis and IBD plus a pipeline of oral peptide candidates for autoimmune diseases to AbbVie’s portfolio
- In addition, AbbVie will also get Nimble's peptide synthesis, screening & optimization platform for rapid peptide discovery and optimization across various targets
Ref: AbbVie| Image: AbbVie
Related News:- AbbVie Reports Results from the P-III (TEMPO-2) Study of Tavapadon for Parkinson's Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
